Lidocaine and Prevention of Chronic Pain

NACompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

January 31, 2015

Conditions
Surgery
Interventions
DRUG

.9 normal saline placebo

Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.

DRUG

Group L (lidocaine)

Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.

Trial Locations (1)

60611

Prentice Womens' Hospital, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER

NCT01619852 - Lidocaine and Prevention of Chronic Pain | Biotech Hunter | Biotech Hunter